# Epigenetic and Liquid Biopsy Biomarkers in Prostate Cancer: Bridging Tumor Heterogeneity and Clinical Implementation

## TL;DR

This paper reviews how epigenetic changes and liquid biopsies can improve prostate cancer diagnosis and treatment by offering more accurate and personalized tools.

## Contribution

The paper provides a comprehensive review of current epigenetic and liquid biopsy biomarkers for prostate cancer and their potential clinical utility.

## Key findings

- Epigenetic alterations and liquid biopsy markers offer better tumor insights than traditional methods like PSA.
- Combining multiple biomarkers with clinical data could enhance prostate cancer risk stratification and treatment decisions.
- Current assays like PCA3 and ConfirmMDx are being used, but further validation is needed for broader clinical adoption.

## Abstract

Prostate cancer is one of the most common cancers in men and is characterized by substantial intertumoral heterogeneity, which makes diagnosis and treatment challenging. Conventional tests, such as prostate-specific antigen measurement, do not always reliably identify aggressive disease or predict treatment response. Recent research indicates that epigenetic alterations and tumor-derived material detected in blood or urine can provide more accurate information about tumor biology. This review summarizes current knowledge on epigenetic biomarkers and liquid biopsy approaches, including analyses based on DNA, RNA, and circulating tumor cells. The main intention of this review is to present the current status of various biomarkers and to assess whether they are, or have the potential to be, routinely used in clinical practice based on current data and guidelines. We discuss how these tools may help reduce unnecessary biopsies, improve risk stratification, and support more personalized treatment decisions. Integrating these biomarkers into clinical practice in the future could improve prostate cancer management and patient outcomes; however, many still require further validation and optimization, for example, by combining multiple biomarkers with other clinical data.

Prostate cancer (PCa) is the most common malignancy in men, characterized by significant genetic and epigenetic heterogeneity, which complicates both diagnosis and treatment processes. Epigenetic mechanisms—including DNA methylation, chromatin remodeling, and dysregulated non-coding RNAs (miRNAs, lncRNAs, circRNAs)—contribute to tumor initiation, progression, and therapy resistance, offering promising diagnostic and prognostic biomarker opportunities. Liquid biopsy technologies, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes, allow minimally invasive, real-time monitoring of tumor evolution and resistance mechanisms, complementing traditional biomarkers like PSA and supporting precision oncology approaches. Clinically implemented assays, including PCA3, ConfirmMDx, and ExoDx Prostate, along with emerging multi-analyte panels, enhance risk stratification, reduce unnecessary biopsies, and guide therapeutic decisions. Integration of epigenetic and liquid biopsy biomarkers into multimodal diagnostic pathways has the potential to support personalized management of prostate cancer; however, many still require further validation and optimization.